SCHEMBL25318677

SCHEMBL25318677

CCCCCCCCCCN(CCCCCCCCCC)C(=O)CCCCCCCN(CCCCCCCC(=O)N(CCCCCCCCCC)CCCCCCCCCC)CCCn1ccnc1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
KMT2A Q03164 2/20 0.52
POLB P06746 1/20 0.52
KDM5A P29375 3/20 0.40
PHF8 Q9UPP1 2/20 0.40
KDM4C Q9H3R0 1/20 0.40
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA9 Q16790 1/20 0.38
TLR8 Q9NR97 2/20 0.38
KDM4E B2RXH2 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CA4 P22748 1/20 0.35
FDPS P14324 1/20 0.35
ICMT O60725 1/20 0.35
ALB P02768 1/20 0.35
THRA P10827 1/20 0.35
THRB P10828 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27220850 0.86 ALDH1A1 (0.70) ALDH1A1KMT2APOLBCA12CA1
SCHEMBL27220890 0.86 ALDH1A1 (0.70) ALDH1A1KMT2APOLBCA12CA1
SCHEMBL27220840 0.86 ALDH1A1 (0.70) ALDH1A1KMT2APOLBCA12CA1
SCHEMBL27220895 0.85 ALDH1A1 (0.72) ALDH1A1KMT2APOLBCA12CA1
SCHEMBL27220838 0.81 ALDH1A1 (0.74) ALDH1A1KMT2APOLBCA12CA1
SCHEMBL25125923 0.81 ALDH1A1 (0.46) ALDH1A1KMT2APOLBTLR8KDM4E
SCHEMBL30357775 0.81 ALDH1A1 (0.51) ALDH1A1KMT2APOLBCA12CA1
SCHEMBL30572233 0.81 ALDH1A1 (0.51) ALDH1A1KMT2APOLBCA12CA1
SCHEMBL23483339 0.80 ALDH1A1 (0.45) ALDH1A1KMT2APOLBTLR8KDM4E
SCHEMBL27220886 0.78 ALDH1A1 (0.69) ALDH1A1KMT2APOLBCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188020-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS ACUITAS THERAPEUTICS INC (CA) 2025-06-12 US disclosed
US-12129223-B2 Lipids for use in lipid nanoparticle formulations Acuitas Therapeutics, Inc. (CA) 2024-10-29 US disclosed
EP-4448485-A2 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2024-10-23 EP disclosed
CN-118647600-A Lipids for lipid nanoparticle formulations 爱康泰生治疗公司 2024-09-13 CN disclosed
US-20230295075-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2023-09-21 US disclosed
US-20230295075-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2023-09-21 US disclosed
US-20230295075-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2023-09-21 US disclosed
WO-2023114943-A2 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2023-06-22 WO disclosed
WO-2023114943-A2 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295075-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS PHOSPHO1, SGMS1, NPC1 ALDH1A1 1138/4885KMT2A 2334/4885POLB 4294/4885
US-20250188020-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS PHOSPHO1, SGMS1, NPC1 ALDH1A1 1138/4885KMT2A 2334/4885POLB 4294/4885
US-12129223-B2 Lipids for use in lipid nanoparticle formulations PHOSPHO1, SGMS1, NPC1 ALDH1A1 1138/4885KMT2A 2334/4885POLB 4294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.